In acute myeloid leukemia (AML), risk stratification based on cytogenetics and mutation profiling is essential but remains insufficient to select the optimal therapy. Accurate biomarkers are needed to improve prognostic assessment. We analyzed RNA sequencing and survival data of 430 AML patients and identified HMGA2 as a novel prognostic marker. We validated a quantitative PCR test to study the association of HMGA2 expression with clinical outcomes in 358 AML samples. In this training cohort, HMGA2 was highly expressed in 22.3% of AML, mostly in patients with intermediate or adverse cytogenetics. High expression levels of HMGA2 (H + ) were associated with a lower frequency of complete remission (58.8% vs 83.4%, P < 0.001), worse 3-year overall survival (OS, 13.2% vs 43.5%, P < 0.001) and relapse-free survival (RFS, 10.8% vs 44.2%, P < 0.001). A positive HMGA2 test also identified a subgroup of patients unresponsive to standard treatments. Multivariable analyses showed that H + was independently associated with significantly worse OS and RFS, including in the intermediate cytogenetic risk category. These associations were confirmed in a validation cohort of 260 patient samples from the UK NCRI AML17 trial. The HMGA2 test could be implemented in clinical trials developing novel therapeutic strategies for high-risk AML.
Conflict of interest statement
The authors declare that they have no conflict of interest.
High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.J Transl Med. 2019 Jun 6;17(1):191. doi: 10.1186/s12967-019-1926-z. J Transl Med. 2019. PMID: 31171000 Free PMC article.
A cytogenetic model predicts relapse risk and survival in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation in morphologic complete remission.Leuk Res. 2015 Jan;39(1):77-81. doi: 10.1016/j.leukres.2014.11.007. Epub 2014 Nov 20. Leuk Res. 2015. PMID: 25481050 Clinical Trial.
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.J Clin Oncol. 2010 Apr 20;28(12):2101-7. doi: 10.1200/JCO.2009.26.0646. Epub 2010 Mar 22. J Clin Oncol. 2010. PMID: 20308656 Clinical Trial.
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813. JAMA. 2009. PMID: 19509382 Free PMC article. Review.
Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.J Hematol Oncol. 2009 Jun 2;2:23. doi: 10.1186/1756-8722-2-23. J Hematol Oncol. 2009. PMID: 19490647 Free PMC article. Review.
Cited by 7 articles
Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.EBioMedicine. 2020 Feb;52:102664. doi: 10.1016/j.ebiom.2020.102664. Epub 2020 Feb 12. EBioMedicine. 2020. PMID: 32062360 Free PMC article.
Cell adhesion to collagen promotes leukemia resistance to doxorubicin by reducing DNA damage through the inhibition of Rac1 activation.Sci Rep. 2019 Dec 19;9(1):19455. doi: 10.1038/s41598-019-55934-w. Sci Rep. 2019. PMID: 31857649 Free PMC article.
Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia.Version 2. Leukemia. 2020 Feb;34(2):427-440. doi: 10.1038/s41375-019-0596-4. Epub 2019 Oct 14. Leukemia. 2020. PMID: 31611628 Free PMC article.
Long non-coding RNA-NEAT1, a sponge for miR-98-5p, promotes expression of oncogene HMGA2 in prostate cancer.Biosci Rep. 2019 Sep 24;39(9):BSR20190635. doi: 10.1042/BSR20190635. Print 2019 Sep 30. Biosci Rep. 2019. PMID: 31481527 Free PMC article.
Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.Appl Health Econ Health Policy. 2019 Dec;17(6):827-839. doi: 10.1007/s40258-019-00503-5. Appl Health Econ Health Policy. 2019. PMID: 31392669 Free PMC article.
- MC_UU_00016/11/MRC_/Medical Research Council/United Kingdom
- MR/L008963/1/MRC_/Medical Research Council/United Kingdom
- MC_UU_12009/11/MRC_/Medical Research Council/United Kingdom
- 4050189188/MRC_/Medical Research Council/United Kingdom
- G1000729/MRC_/Medical Research Council/United Kingdom